• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DESIPRAMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • DESIPRAMINE chembl:CHEMBL72 Approved

    Alternate Names:

    DESIPRAMINE
    DESIPRAMINUM
    5-(GAMMA-METHYLAMINOPROPYL)IMINODIBENZYL
    JB-8181
    MONODEMETHYLIMIPRAMINE
    NORIMIPRAMINE
    DESIPRAMIN
    DMI
    EX-4355
    DÉMÉTHYLIMIPRAMINE
    3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE
    TREYZAFAGIT®
    DEMETHYLIMIPRAMINE
    DESMETHYLIMIPRAMINE
    N-(3-METHYLAMINOPROPYL)IMINOBIBENZYL
    5-(Γ-METHYLAMINOPROPYL)IMINODIBENZYL
    NORPRAMIN®
    DESIPRAMINA
    PERTROFANE®
    chemidplus:50-47-5
    pubchem.compound:2995
    chembl:CHEMBL72
    rxcui:3247
    drugbank:01151

    Drug Info:

    FDA Approval Approved before 1982
    Drug Class small molecule
    Drug Indications Antidepressive Agents, Tricyclic
    Year of Approval approved before 1982
    Drug Class antidepressive agents, tricyclic
    Drug Categories antidepressive agents
    Drug Groups investigational
    Drug Categories agents producing tachycardia
    Drug Categories agents that produce hypertension
    Drug Categories agents that reduce seizure threshold
    Drug Categories anticholinergic agents
    Drug Categories combined inhibitors of serotonin/norepinephrine reuptake
    Drug Categories cytochrome p-450 cyp2b6 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2b6 substrates
    Drug Categories cytochrome p-450 cyp2d6 inhibitors (weak)
    Drug Categories cytochrome p-450 cyp2e1 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2e1 inhibitors (weak)
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a4 inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a4 substrates
    Drug Categories cytochrome p-450 cyp3a4 substrates (strength unknown)
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories drugs that are mainly renally excreted
    Drug Categories heterocyclic compounds, fused-ring
    Drug Categories histamine antagonists
    Drug Categories histamine h1 antagonists
    Drug Categories muscarinic antagonists
    Drug Categories neurotoxic agents
    Drug Categories oct1 inhibitors
    Drug Categories oct2 inhibitors
    Drug Categories p-glycoprotein inhibitors
    Drug Categories potential qtc-prolonging agents
    Drug Categories qtc prolonging agents
    Drug Categories serotonergic drugs shown to increase risk of serotonin syndrome
    Drug Categories serotonin 5-ht2 receptor antagonists
    Drug Categories serotonin agents
    Drug Categories serotonin receptor antagonists
    Drug Categories tricyclics and other norepinephrine-reuptake inhibitors
    (5 More Sources)

    Publications:

    Cusack et al., 1994, Binding of antidepressants to human brain receptors: focus on newer generation compounds., Psychopharmacology (Berl.)
    Sawynok et al., 1999, Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat., Pain
    Kornhuber et al., 2010, Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications., Cell. Physiol. Biochem.
    Hurwitz et al., 1994, The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts., Biol. Chem. Hoppe-Seyler
    Kölzer et al., 2004, Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine., FEBS Lett.
    Testai et al., 2004, Regulation of sphingomyelinases in cells of the oligodendrocyte lineage., J. Neurosci. Res.
    Erdreich-Epstein et al., 2005, Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways., Blood
    Zeidan et al., 2006, Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-{alpha}-induced PGE2 production., J. Biol. Chem.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Bürgi et al., 2003, Antidepressant-induced switch of beta 1-adrenoceptor trafficking as a mechanism for drug action., J. Biol. Chem.
    Samnick et al., 2004, Technetium-99m labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-mercapto-2-methylpropylamino)-piperidine and iodine-123 metaiodobenzylguanidine for studying cardiac adrenergic function: a comparison of the uptake characteristics in vascular smooth muscle cells and neonatal cardiac myocytes, and an investigation in rats., Nucl. Med. Biol.
    Mudunkotuwa et al., 1996, Desipramine administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and 5-HT2A binding sites and their relationship to behaviour., Br. J. Pharmacol.
    Matsumoto et al., 1994, Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice., Pharmacol. Biochem. Behav.
    Sapena et al., 1996, Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes., Eur. J. Pharmacol.
    Leathart JB et al., 1998, CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles., Pharmacogenetics
    Bluhm RE et al., 1993, Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report., Clin Pharmacol Ther
    de Vos A et al., 2011, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients., Pharmacogenomics J
    Shimoda K et al., 2000, Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine., Pharmacol Toxicol
    Dahl ML et al., 1992, Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population., Clin Pharmacol Ther
    Vandel P et al., 2004, Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients., Hum Psychopharmacol
    Kawanishi C et al., 2004, Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study., Eur J Clin Pharmacol
    Roberts RL et al., 2004, No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline., Hum Psychopharmacol
    Spina E et al., 1984, Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes., Clin Pharmacol Ther
    Forget P et al., 2008, Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study., J Pain Symptom Manage
    Kirchheiner J et al., 2003, Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics., J Clin Psychopharmacol
    Dahl ML et al., 1996, Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype., Psychopharmacology (Berl)
    Spina E et al., 1997, Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study., Eur J Clin Pharmacol
    Nielsen KK et al., 1994, Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms., Clin Pharmacol Ther
    Chen S et al., 1996, The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry., Clin Pharmacol Ther
    Koski A et al., 2007, A fatal doxepin poisoning associated with a defective CYP2D6 genotype., Am J Forensic Med Pathol
    Brøsen K et al., 1986, Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism., Eur J Clin Pharmacol
    Brøsen K et al., 1988, First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype., Clin Pharmacol Ther
    Schenk PW et al., 2008, Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients., Mol Psychiatry
    Furman KD et al., 2004, Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics., Pharmacogenetics
    Kirchheiner J et al., 2002, Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers., Pharmacogenetics
    Kirchheiner J et al., 2003, Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity., Pharmacogenetics
    Steimer W et al., 2004, Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers., Clin Chem
    Nguyen HQ et al., 2016, The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine., Drug Metab Dispos
    Murphy GM Jr et al., 2001, CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression., Neuropsychopharmacology
    Koski A et al., 2006, CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies., Forensic Sci Int
    Brøsen K et al., 1986, Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype., Clin Pharmacol Ther
    Goetz MP et al., 2005, Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes., J Clin Oncol
    Johnson M et al., 2006, A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment., CNS Spectr
    Hicks JK et al., 2013, Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants., Clin Pharmacol Ther
    1999, Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG)., Clin Pharmacol Ther
    Dalén P et al., 1998, 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes., Clin Pharmacol Ther
    Stephan PL et al., 2006, Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity., Pharmacopsychiatry
    Bergmann TK et al., 2001, Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6., Eur J Clin Pharmacol
    Weinshenker et al., 2002, Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo., Brain Res.
    Paczkowski FA et al., 2007, chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model., J Biol Chem
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Zhu et al., 2004, The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function., Neurochem. Res.
    Zavosh et al., 1999, Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells., Brain Res. Bull.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Bryan-Lluka et al., 2003, chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter., J. Biol. Chem.
    Ordway et al., 2005, Norepinephrine transporter function and desipramine: residual drug effects versus short-term regulation., J. Neurosci. Methods
    Osadchii et al., 2007, Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats., Pflugers Arch.
    Abadie et al., 1996, Modulation of noradrenaline release from isolated human atrial appendages., J. Auton. Nerv. Syst.
    Prenner et al., 2007, Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy., Biochemistry
    Zhou et al., 2006, Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain., J. Neurochem.
    Holmes et al., 2002, Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter., Neuropsychopharmacology
    Hoffman et al., 1998, In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions., J. Neurochem.
    Gould et al., 2006, A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters., Biol. Psychiatry
    Pälvimäki et al., 1996, Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor., Psychopharmacology (Berl.)
    Wu GS et al., 2011, Sequence polymorphisms of MC1R gene and their association with depression and antidepressant response., Psychiatr Genet
  • DESIPRAMINE   SMPD1

    Interaction Score: 3.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    20502000 7945993 14960314 14689449 15705795 16803890


    Sources:
    DrugBank

  • DESIPRAMINE   MC1R

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21052032


    Sources:
    PharmGKB

  • DESIPRAMINE   SLC6A2

    Interaction Score: 0.39

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Specific Action of the Ligand Inhibition

    PMIDs:
    12137927 17428804 9537821 15002740 10424850 11752352 12837768 15814154


    Sources:
    TEND DTC PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology

  • DESIPRAMINE   SLC6A4

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Details of the Assay for Interaction Assay using HEK-293 cells transfected with hSERT

    PMIDs:
    16300628 9537821 12464448 9422361 16140280


    Sources:
    TEND TdgClinicalTrial DrugBank GuideToPharmacology

  • DESIPRAMINE   SLC29A4

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • DESIPRAMINE   ADRB1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12393876 15093822 8730743 7816863 8741184


    Sources:
    TEND TdgClinicalTrial DrugBank

  • DESIPRAMINE   CYP2D6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9918137 8422746 20531370 10895986 1346258 15252821 14652703 14716707 6488689 18359183 14520122 8867869 9049581 8181196 8941025 17721180 3533565 3356084 17667959 15115913 12360109 14646691 15205367 27440861 11682257 16024198 3769385 16361630 17008819 23486447 10460069 9585799 16871470 11417443


    Sources:
    DTC FDA PharmGKB

  • DESIPRAMINE   CHRM2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    7855217 17139284 17016423


    Sources:
    TEND TdgClinicalTrial DrugBank

  • DESIPRAMINE   ADRB2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    17558518 8988485 17417877 7816863 8741184


    Sources:
    TEND TdgClinicalTrial DrugBank

  • DESIPRAMINE   ARSA

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DESIPRAMINE   CHRM1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    7855217 17139284 17016423


    Sources:
    TEND TdgClinicalTrial DrugBank

  • DESIPRAMINE   HRH1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    7855217 10467920


    Sources:
    TEND TdgClinicalTrial DrugBank

  • DESIPRAMINE   CHRM4

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    7855217


    Sources:
    DrugBank

  • DESIPRAMINE   CHRM5

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    7855217


    Sources:
    DrugBank

  • DESIPRAMINE   HTR2C

    Interaction Score: 0.03

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    8876023


    Sources:
    DrugBank

  • DESIPRAMINE   BDNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DESIPRAMINE   ADRA2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    7855217


    Sources:
    DrugBank

  • DESIPRAMINE   CHRM3

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    7855217


    Sources:
    DrugBank

  • DESIPRAMINE   THPO

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DESIPRAMINE   HTR1A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    7855217


    Sources:
    DrugBank

  • DESIPRAMINE   ADRA1A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    7855217


    Sources:
    DrugBank

  • DESIPRAMINE   HTR2A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    7855217


    Sources:
    DrugBank

  • DESIPRAMINE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    7855217


    Sources:
    DrugBank

  • DESIPRAMINE   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DESIPRAMINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC PharmGKB

  • DESIPRAMINE   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DrugBank: DB01151

    • Version: 5.1.7

    Alternate Names:
    DESIPRAMINE DrugBank Drug Name
    50-47-5 CAS Number
    Desipramine Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Osadchii et al., 2007, Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats., Pflugers Arch.
    Abadie et al., 1996, Modulation of noradrenaline release from isolated human atrial appendages., J. Auton. Nerv. Syst.
    Prenner et al., 2007, Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy., Biochemistry

  • TEND: DESIPRAMINE

    • Version: 01-August-2011

    Alternate Names:
    DESIPRAMINE Primary Drug Name

    Drug Info:
    Drug Class antidepressive agents, tricyclic
    Year of Approval approved before 1982

    Publications:

  • TdgClinicalTrial: DESIPRAMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antidepressive Agents, Tricyclic
    Drug Class small molecule
    FDA Approval Approved before 1982

    Publications:

  • DTC: DESIPRAMINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL72 ChEMBL Drug ID

    Drug Info:

    Publications:
    Paczkowski FA et al., 2007, chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model., J Biol Chem

  • PharmGKB: desipramine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Leathart JB et al., 1998, CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles., Pharmacogenetics
    Bluhm RE et al., 1993, Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report., Clin Pharmacol Ther
    de Vos A et al., 2011, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients., Pharmacogenomics J

  • TTD: Desipramine

    • Version: 2020.06.01

    Alternate Names:
    D01UTL TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 135650171

    • Version: 29-September-2020

    Alternate Names:
    DESIPRAMINE GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL72

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Desipramine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2021-04-13